Brand names: Vyndaqel, Vyndamax
2 interactions on record
Coadministration of tafamidis and drugs that are BCRP substrates may increase the exposure of substrates of this transporter (e.g., methotrexate, rosuvastatin, imatinib) and the risk of the substrate-related toxicities.
Source: FDA drug label - tafamidis meglumine
Coadministration of tafamidis and drugs that are BCRP substrates may increase the exposure of substrates of this transporter (e.g., methotrexate, rosuvastatin, imatinib) and the risk of the substrate-related toxicities.
Source: FDA drug label - tafamidis meglumine